Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants
NCT ID: NCT02154984
Last Updated: 2020-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
45 participants
INTERVENTIONAL
2014-07-31
2017-02-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Time-restricted Eating in Peri- and Postmenopausal Women
NCT06188598
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
NCT04893226
Time Restricted Eating on Cancer Risk
NCT05038137
Remote Time-restricted EAting DeliverY
NCT05454943
Early vs. Late Time Restricted Eating vs. Daily Caloric Restriction
NCT05870982
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Feasibility of fostering adherence to self-monitoring of dietary intake using a smartphone application (app).
II. Feasibility of the goal of following a time-restricted diet.
SECONDARY OBJECTIVES:
I. Identify potential molecular biomarkers and/or signatures to explore its efficacy for the normalization of metabolism.
II. Assess the systemic endocrine effects of a time restricted diet (tRD) intervention in overweight and obese pre and postmenopausal women.
III. Assess weight change following a tRD intervention. IV. Evaluate the effects of a tRD intervention, and identify a specific and reproducible genomic signature, in breast samples obtained by random fine needle aspiration in the tRD study population.
V. Assess the volume of parenchymal enhancement on magnetic resonance imaging (MRI).
OUTLINE:
Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.
After completion, participants are followed up for 3 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Behavioral (time restricted diet)
Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.
behavioral dietary intervention
Follow tRD
telephone-based intervention
Receive coaching calls
laboratory biomarker analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
behavioral dietary intervention
Follow tRD
telephone-based intervention
Receive coaching calls
laboratory biomarker analysis
Correlative studies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must have had a normal mammogram within 9 months prior to registration; NOTE: subjects must also have a normal breast exam on the day of the pre-intervention random fine needle aspiration (rFNA)
* Subjects must have a body mass index (BMI) of 25-40
* Subjects must fit into ONE of the following menopausal categories:
* Premenopausal (n = 40) - defined as meeting all the following criteria:
* Have had at least 8 menstrual cycles in the past 12 months
* Have had no hormonal contraception in the past 3 months prior to registration
* Have serum hormone parameters (estradiol \[E2\], progesterone, follicle stimulating hormone \[FSH\]) in premenopausal range on the day of rFNA; NOTE: subjects will self-report menopausal status at registration, and confirmation of hormonal parameters will occur after registration as part of pre-intervention procedures; if there is mis-assignment of status, the recruitment of future subjects will be adjusted accordingly
* Postmenopausal (n = 40) - defined as meeting all of the following criteria:
* Last menstrual period (LMP) \> 1 year previously
* Have had no hormone use in the past 3 months prior to registration
* Serum E2, progesterone, FSH in postmenopausal range on the day of rFNA; NOTE: subjects will self-report menopausal status at registration, and confirmation of hormonal parameters will occur after registration as part of pre-intervention procedures; if there is mis-assignment of status, the recruitment of future subjects will be adjusted accordingly
* Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Subjects who have been diagnosed with a prior cancer at any site (other than breast cancer) may participate as long as they have been off medical therapy for at least 12 months prior to registration
* Subjects with prior breast cancer must be off all systemic therapy (including endocrine agents) for at least 2 years prior to registration
* Subjects must be willing to undergo a random fine needle aspiration (rFNA) at the beginning and end of the intervention period
* Subjects must be willing and able to abstain from the use of aspirin for at least 2 weeks prior to undergoing each rFNA procedure (pre- and post-intervention)
* Subjects must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
* Subjects must have a smart phone (newer generation Android or any Iphone) to be able to track their food intake times
* Subjects must be willing to restrict food intake to an 8 hour period every day (12 pm to 8 pm)
Exclusion Criteria
* Subjects who are pregnant and/or lactating are not eligible
* Subjects who are noted (upon initial online screening) to do 150 minutes or more of moderate level physical activity each week, get less than 8% of their calories from saturated fat, and eat more than 5 fruit and vegetable servings per day will not be eligible
* Subjects who are part of any structured weight loss programs (e.g. Weight Watchers, etc.) are not eligible
* Subjects who have undergone bariatric surgery are not eligible
* Subjects who work night shifts are not eligible
* Subjects who have diabetes or uncontrolled hypertension are not eligible; NOTE: for the purposes of this study, uncontrolled will be defined as diastolic pressure over 100 mmHg
18 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Avon Foundation Center of Excellence
UNKNOWN
National Cancer Institute (NCI)
NIH
Northwestern University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seema Khan
Role: PRINCIPAL_INVESTIGATOR
Northwestern University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northwestern University
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2014-01094
Identifier Type: REGISTRY
Identifier Source: secondary_id
STU00091568
Identifier Type: -
Identifier Source: secondary_id
NU 13CC12
Identifier Type: OTHER
Identifier Source: secondary_id
NU 13CC12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.